NASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free IMMX Stock Alerts $2.31 +0.14 (+6.45%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$2.11▼$2.3750-Day Range$2.10▼$3.7052-Week Range$1.40▼$7.75Volume88,130 shsAverage Volume247,374 shsMarket Capitalization$60.99 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immix Biopharma alerts: Email Address Immix Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside527.8% Upside$14.00 Price TargetShort InterestHealthy2.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.91) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.86 out of 5 starsMedical Sector387th out of 924 stocksPharmaceutical Preparations Industry170th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingImmix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmix Biopharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.53% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immix Biopharma has recently decreased by 10.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMX. Previous Next 3.1 News and Social Media Coverage News SentimentImmix Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immix Biopharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows5 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders55.90% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.26% of the stock of Immix Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immix Biopharma are expected to decrease in the coming year, from ($0.91) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Immix Biopharma Stock (NASDAQ:IMMX)Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Read More IMMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMX Stock News HeadlinesMay 1, 2024 | americanbankingnews.comShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Decreases By 10.0%May 1, 2024 | americanbankingnews.comImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Drop in Short InterestMay 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 29, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 29, 2024 | globenewswire.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 18, 2024 | finance.yahoo.comImmix Biopharma, Inc. (IMMX)April 18, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United StatesApril 18, 2024 | globenewswire.comImmix Biopharma on Track to Dose NXC-201 Patients in United StatesMay 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 15, 2024 | globenewswire.comImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)April 2, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023March 20, 2024 | globenewswire.comImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical TrialMarch 7, 2024 | stockhouse.comImmix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness InitiativeMarch 5, 2024 | globenewswire.comImmix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness InitiativeFebruary 24, 2024 | msn.comImmix Biopharma (IMMX) Price Target Increased by 27.27% to 14.28February 22, 2024 | finance.yahoo.comIMMX Apr 2024 7.500 callFebruary 21, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | markets.businessinsider.comImmix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | finance.yahoo.comImmix Biopharma 12 Month Review Progress UpdateFebruary 21, 2024 | globenewswire.comImmix Biopharma 12 Month Review Progress UpdateFebruary 13, 2024 | finance.yahoo.comIMMX Aug 2024 2.500 callFebruary 8, 2024 | finance.yahoo.comImmix Biopharma Announces Closing of $15 Million Public Offering of Common StockFebruary 8, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL AmyloidosisFebruary 7, 2024 | markets.businessinsider.comImmix Biopharma Signs Definitive $15M Titan Partnership DealFebruary 7, 2024 | finance.yahoo.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL AmyloidosisFebruary 6, 2024 | msn.comImmix Biopharma Suspends Stock Offering Pending New ProspectusFebruary 5, 2024 | finance.yahoo.comImmix Biopharma Announces Pricing of $15 Million Public Offering of Common StockSee More Headlines Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/02/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMMX CUSIPN/A CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+545.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-101.56% Return on Assets-86.70% Debt Debt-to-Equity RatioN/A Current Ratio5.32 Quick Ratio5.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book2.68Miscellaneous Outstanding Shares26,400,000Free Float11,641,000Market Cap$57.29 million OptionableOptionable Beta0.25 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ilya Rachman M.B.A. (Age 51)M.D., MBA, Ph.D., Co-Founder, CEO & Chairman Comp: $637.5kMr. Gabriel Morris B.A. (Age 37)CFO & Director Comp: $637.5kMr. Sean Senn J.D.M.B.A., M.Sc., MBA, MSc, Co-FounderDr. Vladimir P. Torchilin D.Sc. (Age 77)MSE, Ph.D., Scientific Co-Founder Mr. Ben H. Lyon J.D.Executive VP & General CounselDr. Graham Ross FFPM (Age 64)M.D., Chief Medical Officer & Head of Clinical Development Mr. Nandan Oza B.S. (Age 62)Head of Chemistry, Manufacturing & Control Dr. David MarksChief Medical Officer of Cell TherapyMr. Gerhard BauerHead of Cell Thearpy ManufacturingMore ExecutivesKey CompetitorsCelularityNASDAQ:CELUReneo PharmaceuticalsNASDAQ:RPHMCleneNASDAQ:CLNNEledon PharmaceuticalsNASDAQ:ELDNJaguar HealthNASDAQ:JAGXView All CompetitorsInsiders & InstitutionsTritonpoint Wealth LLCBought 24,526 shares on 4/26/2024Ownership: 0.093%Jump Financial LLCBought 18,500 shares on 2/7/2024Ownership: 0.093%Private Advisor Group LLCBought 99,775 shares on 2/6/2024Ownership: 0.502%Jason HsuBought 31,000 shares on 12/11/2023Total: $144,770.00 ($4.67/share)Jason HsuBought 25,000 shares on 12/8/2023Total: $122,000.00 ($4.88/share)View All Insider TransactionsView All Institutional Transactions IMMX Stock Analysis - Frequently Asked Questions Should I buy or sell Immix Biopharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMMX shares. View IMMX analyst ratings or view top-rated stocks. What is Immix Biopharma's stock price target for 2024? 1 Wall Street analysts have issued 1 year target prices for Immix Biopharma's stock. Their IMMX share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 527.8% from the stock's current price. View analysts price targets for IMMX or view top-rated stocks among Wall Street analysts. How have IMMX shares performed in 2024? Immix Biopharma's stock was trading at $6.92 on January 1st, 2024. Since then, IMMX shares have decreased by 67.8% and is now trading at $2.23. View the best growth stocks for 2024 here. Are investors shorting Immix Biopharma? Immix Biopharma saw a decline in short interest in April. As of April 15th, there was short interest totaling 349,900 shares, a decline of 10.0% from the March 31st total of 388,800 shares. Based on an average daily volume of 278,000 shares, the short-interest ratio is currently 1.3 days. Approximately 2.5% of the company's stock are sold short. View Immix Biopharma's Short Interest. When is Immix Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our IMMX earnings forecast. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) announced its earnings results on Friday, March, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an IPO on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share. Who are Immix Biopharma's major shareholders? Immix Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Tritonpoint Wealth LLC (0.09%). Insiders that own company stock include Carey Ng, Helen C Adams, Ilya M Rachman, Jason Hsu, Magda Marquet, Melissa Jane Buchan and Sean Senn. View institutional ownership trends. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMMX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
